相关实验视频

Updated: Jun 30, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

梅特福林使用与地理缩的新出现的ICD编码之间的关联

John Moir¹, Max J Hyman², Reem Gonnah³

¹Pritzker School of Medicine, University of Chicago, Chicago, Illinois, United States.

Investigative ophthalmology & visual science

|March 18, 2024

概括

甲福明可以降低患地理缩 (GA) 的风险,这是严重的与年龄相关的黄斑变性 (AMD). 这项研究表明,甲福明可能是GA的有前途的预防剂.

科学领域:

眼科医生眼科眼科
老年学是一门学科.
药理学药理学是指药理学的学科.

背景情况:

与年龄相关的黄斑变性 (AMD) 是老年人视力丧失的主要原因.
地理缩 (GA) 是一种严重的,不可逆转的AMD亚型.
在观察性研究中,一种常见的糖尿病药物甲胺已经显示出对AMD的潜在保护作用.

研究的目的:

调查甲福明使用与地理缩 (GA) 发病率之间的关联.
在大型患者数据库中分析甲福明对GA发育的影响.

主要方法:

使用Merative MarketScan商业和医疗保险数据库 (2017-2021) 进行了一项病例控制研究.
60岁以上的GA新发病患者与没有GA的对照人群进行了匹配,使用倾向分数.
在指数访问前一年评估了甲胺暴露;用于分析的多变量逻辑回归.

主要成果:

在整体队列中 (10,505个GA病例),甲福明的使用与新发动的GA的几率降低了12%.
在一个没有糖尿病的小组 (7,611个GA病例) 中,甲福明的使用与新发性GA的几率降低了47%.
这些发现被调整以考虑AMD风险因素和并发症.

结论:

甲福明可以作为一种潜在的非侵入性药物来预防GA.
鉴于GA目前的治疗局限性以及甲福明的良好的安全性,这些发现很重要.
需要进一步的研究和临床试验来验证这些结果.

更多相关视频

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

相关概念视频

Diabetes: Symptoms, Diagnosis, and Complications

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...